Bruker (NASDAQ:BRKR) Shares Down 7.1% – Here’s Why

Bruker Corporation (NASDAQ:BRKR) shares dropped 7.1% on Wednesday . The company traded as low as $55.08 and last traded at $54.21. Approximately 230,821 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 2,339,288 shares. The stock had previously closed at $58.37.

Analyst Upgrades and Downgrades

BRKR has been the subject of several recent analyst reports. Stifel Nicolaus set a $50.00 price target on Bruker in a report on Wednesday, August 5th. Wolfe Research initiated coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating for the company. Barclays upped their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Guggenheim raised their price objective on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Citigroup lowered their target price on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $57.00.

Bruker Trading Down 6.7%

The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The business has a 50 day moving average of $58.70 and a 200-day moving average of $49.00. The stock has a market cap of $8.30 billion, a PE ratio of -77.73, a price-to-earnings-growth ratio of 1.79 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently made changes to their positions in BRKR. Los Angeles Capital Management LLC purchased a new position in Bruker in the fourth quarter valued at approximately $26,000. Allworth Financial LP grew its position in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares in the last quarter. Essential Partners LLC purchased a new stake in shares of Bruker during the first quarter valued at approximately $36,000. Global Retirement Partners LLC purchased a new position in shares of Bruker in the second quarter valued at $38,000. Finally, Parallel Advisors LLC grew its holdings in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.